Development of the novel PEG-PE-based polymer for the reversible attachment of specific ligands to liposomes: synthesis and in vitro characterization.

Surface grafting of liposomes with the wide variety of ligands including antibodies and other proteins is a promising approach for targeted delivery of therapeutics. In this paper, we describe a simple method of synthesizing a hydrazine-functionalized poly(ethylene glycol)-phosphatidylethanolamine (PEG-PE)-based amphiphilic polymer which can conjugate a variety of ligands via a reversible, pH-cleavable bond. In this method, the targeting ligand is attached to the distal end of the PEG chain, which facilitates its easy access to the targeted site of interaction. The reversible attachment of targeting ligands is useful especially in multifunctional liposomal systems, whereafter successfully performing the function of targeting to the specific site, the bulky ligands, such as proteins or antibodies, are cleaved off in response to an environmental stimulus to expose some other functionalities such as ligands for intracellular penetration or organelle-specific targeting. To investigate the applicability of the protocol, the model ligands monoclonal antinucleosome antibody 2C5 and antimyosin antibody 2G4, and glycoproteins concanavalin A (Con-A) and avidin were conjugated to the synthesized polymer and incorporated into liposomes. In vitro assays including biochemical, enzyme-linked immunosorbent, fluorescence microscopy, and flow cytometry were used to confirm three key characteristics of the modified and/or liposome-attached proteins: successful conjugation of the targeting ligands to the polymer, preservation of specific activity of the ligands after the conjugation and liposome attachment, and the facile pH-sensitive ligand detachment. Monoclonal antibody 2C5 and 2G4, immobilized on the liposome surface, retained their binding affinity to corresponding antigens as confirmed by ELISA. The Con A-bearing liposomes showed significantly higher agglutination in the presence of its substrate mannan compared to plain liposomes (PL) and avidin-functionalized liposomes bound specifically with biotin-agarose. The study on the pH-dependence showed that almost 80% of the hydrazone bond was cleaved after rather brief preincubation of the immunoliposomes at pH 5 for 0.5 to 1 h. Fluorescence microscopy and flow cytometry analysis of cancer cells (HeLa and MCF-7) treated with cancer cell-specific targeting ligand mAb 2C5-bearing liposomes showed enhanced cellular binding. Studies at low pH clearly confirmed the easy cleavability of the targeting ligand from the liposomes resulting in significantly less or virtually no cellular association.

[1]  Vladimir P Torchilin,et al.  Passive and active drug targeting: drug delivery to tumors as an example. , 2010, Handbook of experimental pharmacology.

[2]  V. Torchilin,et al.  Targeted accumulation of polyethylene glycol‐coated immunoliposomes in infarcted rabbit myocardium , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  G Gregoriadis,et al.  Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. , 1991, Biochimica et biophysica acta.

[4]  J. Cohen,et al.  Sterically stabilized liposomes: physical and biological properties. , 1994, Journal of drug targeting.

[5]  V. Torchilin,et al.  Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. , 1991, Biochimica et biophysica acta.

[6]  H. Enoch,et al.  Formation and properties of 1000-A-diameter, single-bilayer phospholipid vesicles. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[7]  V. Torchilin,et al.  "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. , 2006, Bioconjugate chemistry.

[8]  V. Torchilin Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[9]  H. Gold,et al.  Acute myocardial infarct imaging with indium-111-labeled monoclonal antimyosin Fab. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  G. Ellman,et al.  Tissue sulfhydryl groups. , 1959, Archives of biochemistry and biophysics.

[11]  Vladimir P Torchilin,et al.  Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. , 2005, Advanced drug delivery reviews.

[12]  H. Gold,et al.  Monoclonal antibody to cardiac myosin: imaging of experimental myocardial infarction. , 1984, Hybridoma.

[13]  T. Allen,et al.  Ligand-targeted liposomes for cancer treatment. , 2005, Current drug delivery.

[14]  S. Zalipsky Synthesis of an end-group functionalized polyethylene glycol-lipid conjugate for preparation of polymer-grafted liposomes. , 1993, Bioconjugate chemistry.

[15]  V. Torchilin,et al.  p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. , 2001, Biochimica et biophysica acta.

[16]  Samuel Zalipsky,et al.  Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. , 2004, Advanced drug delivery reviews.

[17]  V. Torchilin,et al.  Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. , 1996, Biochimica et biophysica acta.

[18]  V. Torchilin,et al.  “Smart” Drug Carriers: PEGylated TATp-Modified pH-Sensitive Liposomes , 2007, Journal of liposome research.

[19]  Robert Langer,et al.  Lectin-bearing Polymerized Liposomes as Potential Oral Vaccine Carriers , 1996, Pharmaceutical Research.

[20]  Willis,et al.  Ligand-targeted liposomes. , 1998, Advanced drug delivery reviews.

[21]  A A Bogdanov,et al.  Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. , 1994, Biochimica et biophysica acta.

[22]  M. Woodle,et al.  Sterically stabilized liposomes. , 1992, Biochimica et biophysica acta.

[23]  F. Muggia Clinical Efficacy and Prospects for Use of Pegylated Liposomal Doxorubicin in the Treatment of Ovarian and Breast Cancers , 2012, Drugs.

[24]  V. Torchilin,et al.  Nucleosome-releasing treatment makes surviving tumor cells better targets for nucleosome-specific anticancer antibodies. , 1998, Cancer detection and prevention.

[25]  A. Habeeb,et al.  Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. , 1966, Analytical biochemistry.

[26]  A. Zimmer,et al.  Drug delivery of oligonucleotides by peptides. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[27]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[28]  V. Torchilin,et al.  Anti-nuclear autoantibodies of the aged reactive against the surface of tumor but not normal cells. , 1995, Immunology letters.

[29]  G. Hortobagyi,et al.  Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Zalipsky Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. , 1995, Bioconjugate chemistry.

[31]  Qiang Zhang,et al.  Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. , 2005, Journal of pharmaceutical sciences.

[32]  T. N. Palmer,et al.  The mechanism of liposome accumulation in infarction. , 1984, Biochimica et biophysica acta.

[33]  Vladimir P Torchilin,et al.  Multifunctional nanocarriers. , 2006, Advanced drug delivery reviews.